Hui Sheng Biopharmaceutical, a subsidiary of Hong Kong-listed Sihuan Pharmaceutical Holdings Group, has secured 580 million yuan ($85.6 million) in a Series A+ round, bringing its post-investment valuation at 5.58 billion yuan ($823.6 million), according to a filing on the Hong Kong Stock Exchange on January 3.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
